Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arzoxifene in refractory ovarian cancer
NCT00003670Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 1998
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of arzoxifene in ovarian cancer, primary peritoneal cancer (PPC), sponsored by Eli Lilly and Company. Started Oct 1998; status: completed.
02
Drugs
arzoxifene
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00003670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003670.